Journal
CANCER INVESTIGATION
Volume 41, Issue 1, Pages 93-100Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357907.2022.2134414
Keywords
Anti-EGFR; cetuximab; head and neck cancer; treatment; R; M-HNSCC
Categories
Ask authors/readers for more resources
The application of cetuximab in palliative first-line therapy for R/M HNSCC patients can significantly improve overall survival, according to the study.
Patients with R/M HNSCC treated with palliative first-line therapy at Hannover Medical School between October 2005 and December 2016 have been included to show changes in survival following broad utilization of cetuximab. Treatment periods were defined from 10/2005 to 12/2008 (Period A) and 01/2009 to 12/2016. Overall survival did not improve over time. However, in subgroup analysis cetuximab utilized at any time vs. never showed a significant improve of overall survival (11.3 vs. 6.3 months, HR: 0.55, 95%-CI: 0.4-0.8, p = 0.04). Therefore, this study supports the application of cetuximab in this real-world population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available